Sugammadex Piramal 유럽 연합 - 슬로바키아어 - EMA (European Medicines Agency)

sugammadex piramal

piramal critical care b.v. - sugammadex sodium - neuromuskulárna blokáda - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

Sugammadex Mylan 유럽 연합 - 슬로바키아어 - EMA (European Medicines Agency)

sugammadex mylan

mylan ireland limited - sugammadex sodium - neuromuskulárna blokáda - všetky ostatné terapeutické produkty - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Sugammadex Fresenius Kabi 유럽 연합 - 슬로바키아어 - EMA (European Medicines Agency)

sugammadex fresenius kabi

fresenius kabi deutschland gmbh - sugammadex sodium - neuromuskulárna blokáda - všetky ostatné terapeutické produkty - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Sugammadex Amomed 유럽 연합 - 슬로바키아어 - EMA (European Medicines Agency)

sugammadex amomed

aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskulárna blokáda - všetky ostatné terapeutické produkty - zvrat neuromuskulárnej blokády indukovanej rokurónom alebo vekuróniom. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Sugammadex Adroiq 유럽 연합 - 슬로바키아어 - EMA (European Medicines Agency)

sugammadex adroiq

extrovis eu ltd. - sugammadex sodium - neuromuskulárna blokáda - všetky ostatné terapeutické produkty - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

DaTSCAN 유럽 연합 - 슬로바키아어 - EMA (European Medicines Agency)

datscan

ge healthcare b.v. - ioflupán (123 i) - tomography, emission-computed, single-photon; lewy body disease; parkinson disease; alzheimer disease - diagnostické rádiofarmaká - tento liek je určený len na diagnostické účely. datscan je určený pre detekciu straty funkčné dopaminergic neurón terminálov v striatum:u dospelých pacientov s klinicky neistý parkinsonian syndrómov, napríklad tých s včasné príznaky, s cieľom pomôcť rozlíšiť základné chvenie z parkinsonian syndrómy spojené s idiopatickej parkinsonovej choroby, viaceré systémové atrofie a progresívne supranuclear obrnou. datscan nie je schopný rozlišovať medzi parkinsonova choroba, viaceré systémové atrofie a progresívne supranuclear obrnou. u dospelých pacientov, pomôcť odlíšiť pravdepodobné, demencie s lewy orgánov od alzheimerovej choroby. datscan nie je schopný rozlišovať medzi demenciou s lewy orgánov a parkinsonova choroba, demencia.